Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Cytarabine in Relapsed/Refractory AML or High-Risk MDS
NCT00569010Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2005
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2005; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00569010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00569010.